gavinpublishers.comの競合サイトトップ10

scirp.org

Publish academic research as peer-reviewed open access books with SCIRP Books.

tandfonline.com

search and explore the millions of quality, peer-reviewed journal articles published under the taylor & francis and routledge imprints.

ijrar.org

ugc-care list, new ugc-care reference list, ugc care journals, ugc care list of journal, ugc care list, ugc approved list, list of ugc approved journal, ugc approved journal,ijrar - international research journal,ijrar.org,ijrar.org, international journal of research and analytical reviews (ijrar) , ugc approved journal, ugc approved,ugc, ugc certify, publish free of cost, free publication, ugc and issn approved , international peer reviewed, open access journal , e issn 2348 –1269, print issn 2349-5138, issn: 2348 –1269, impact factor : 5.75 , e- journal, low cost inr 500, free publication

sciencedirect.com

sciencedirect is the world's leading source for scientific, technical, and medical research. explore journals, books and articles.

ar.iiarjournals.org

Background/Aim: T-cell receptor recombination sequencing reads have been extracted from genomics files and have been characterized and correlated with patient outcomes for many different cancer types. Materials and Methods: An immunogenomics approach was applied to endemic Burkitt lymphoma (BL) utilizing the Cancer Genome Characterization Initiative – Burkitt Lymphoma Genome Sequencing Project (CGCI-BLGSP), focusing on TCR V- or J- gene segment, HLA allele combinations and anti-HIV CDR3s. Results: Results indicated that five TCR V- or J- gene segment, HLA allele combinations were associated with overall survival (OS) distinctions where the individual arms of the combinations were not associated with survival. Anti-HIV analyses indicated that those cases with an anti-HIV TRA CDR3 had a higher OS probability than those without (median OS not reached vs . 215 days; log-rank p =0.0013), and those with anti-HIV TRA and TRB CDR3s had better pathologic staging compared to those without. Conclusion: T-cell response leads to early control of progression of endemic BL.

effepharm.com

effepharm (shanghai) co., ltd

wonkhe.com

your default content